Aptevo Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 14, 2025
APVO$1.13-8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $8,714 | $16,904 |
| Prepaid expenses | 1,689 | 1,473 |
| Other current assets | 256 | 689 |
| Total current assets | 10,659 | 19,066 |
| Property and equipment, net | 543 | 895 |
| Operating lease right-of-use asset | 4,389 | 4,881 |
| Total assets | $15,591 | $24,842 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and other accrued liabilities | $3,053 | $3,984 |
| Accrued compensation | 1,856 | 2,098 |
| Other current liabilities | 1,298 | 1,142 |
| Total current liabilities | 6,207 | 7,224 |
| Other long-term liabilities | — | — |
| Operating lease liability | 4,629 | 5,397 |
| Total liabilities | 10,836 | 12,621 |
| Stockholders' equity: | ||
| Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding | — | — |
| Common stock: $0.001 par value; 500,000,000 shares authorized; 1,458,443 and 11,958 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 84 | 61 |
| Additional paid-in capital | 252,248 | 235,607 |
| Accumulated deficit | (247,577) | (223,447) |
| Total stockholders' equity | 4,755 | 12,221 |
| Total liabilities and stockholders' equity | $15,591 | $24,842 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.